Regulatory approval trends and market access implications: a multiregional comparative framework for new and supplemental drug applications (2020–2025)
Expert Review of Pharmacoeconomics & Outcomes Research · 09.08.2026 · 26 (7) · 933-947
DOI: 10.1080/14737167.2026.2715979 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 10.08.2026. Verfasst von Mohit Bajaj und 1 weiteren Autor:innen. Beteiligte Einrichtung: Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS (Deemed to Be University), Mumbai, India. Hauptthemen laut MEDLINE: Drug Approval, Drug Industry. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Drug approval remains fragmented, governed by region-specific regulatory frameworks and review pathways. Despite international harmonization, the same product is often approved at different timelines and under different pathways across regions, complicating regulatory planning. Currently, there is no unified system that enables concurrent comparison of multiregional drug approvals. METHODS: Drug Approvals in the US, EU, Japan, and India were evaluated from Jan-2020 to June-2025. NDA approvals were assessed year-wise, review type, and by pharmacotherapeutic area to identify key focus areas. Supplemental approvals were analyzed year-wise, application categorywise, and by therapeutic area to understand post-approval patterns. This study analyses multiregional approval trends and addresses this gap through an integrated analytical framework. To enable integrated multiregional assessment, a web-based regulatory intelligence dashboard was developed. RESULTS: The dashboard consolidates approval data across regions and parameters into a harmonized interface for simultaneous visualization, comparison and assessment across multiple jurisdictions. For pharmaceutical manufacturers, the availability of such a platform enables monitoring of approval patterns, identifying unapproved or underexplored markets and supporting data-driven strategic planning for earlier market access. The dashboard provides regulatory authorities, sponsors, researchers and policy makers consolidated visibility into cross-regional activity. CONCLUSION: Overall, the dashboard enables data-driven comparison by addressing a gap in existing information systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS (Deemed to Be University), Mumbai, India.
Zitieren
APA
Bajaj, M., & Patel, M. (2026). Regulatory approval trends and market access implications: a multiregional comparative framework for new and supplemental drug applications (2020–2025). Expert Review of Pharmacoeconomics & Outcomes Research, 26(7), 933-947. https://doi.org/10.1080/14737167.2026.2715979
Vancouver
Bajaj M, Patel M. Regulatory approval trends and market access implications: a multiregional comparative framework for new and supplemental drug applications (2020–2025). Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(7):933-947. doi:10.1080/14737167.2026.2715979
BibTeX
@article{Bajaj2026,
author = {Bajaj, Mohit and Patel, Mital},
title = {Regulatory approval trends and market access implications: a multiregional comparative framework for new and supplemental drug applications (2020–2025)},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
volume = {26},
number = {7},
pages = {933--947},
doi = {10.1080/14737167.2026.2715979}
}
EUVIMED